Biofidelity
Business Services · United Kingdom · 11-50 Employees
View Company Info for Free
Overview
Headquarters
330 Cambridge Science Park, Milton Road,...Phone Number
+44 1223981750Website
www.biofidelity.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
2
1
1
1
1
1
About Biofidelity
Biofidelity, a private company founded in 2019 in Cambridge, UK, is revolutionizing access to best-in-class cancer diagnostics, breaking down the barriers to better screening, monitoring and treatment for all cancer patients. Its disruptive diagnostic technology platform provides oncologists with clinically actionable data based on ultra-sensitive detection of markers recommended in cancer treatment guidelines, enabling them to prescribe the right cancer drug at the right time. It is designed to combine fast and easy-to-interpret results with affordability and straightforward adoption on existing laboratory infrastructure, enabling many more laboratories to offer high quality cancer diagnostics.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Biofidelity your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if Biofidelity had a recent Job posting/layoffs
Product Launch: Get notified when Biofidelity launches new products
Check if Biofidelity has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on Biofidelity recently announced quarterly report
Check out if Biofidelity is spiking on competitors!
Funding: Get notified immidiatlly once Biofidelity has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at Biofidelity
Website visits: Recent activity has been detected on your website
Biofidelity, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Reach out to Masked Content who joined Biofidelity as Masked Content
Find more new buyers
Compare Similar Companies to Biofidelity
Compare insights from companies similar to Biofidelity, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Biofidelity
<$5M
11-50
Private
$66.5M
2019
N/A
Company Profile Activity
Activity Insights
Biofidelity is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Biofidelity is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Biofidelity.
Biofidelity financials insights
Gather financial insights about Biofidelity, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2017
Unspecified
$6.5M
2022
Series A
$36M
2024
Other Financing Round
$24M
Biofidelity Tech Stack
A closer look at the technologies used by Biofidelity
Most Recent Scoops
Left Company
Executive Move
Executive Moves, Left Company
Event
Product Marketing, Events, Training, Medical Research, Field /Outside Sales, Clinical Operations, Field Marketing, Healthcare Technology
Person-Based
Event
Product Marketing, Events, Software, Field /Outside Sales, Field Marketing, Healthcare Operations, Healthcare Technology
Person-Based
Biofidelity News & Media
Next Generation Tissue Biomarkers Market Research 2025: Market to Double by 2030 with a Surge in Demand for Personalized Medicines, Biofidelity's Enspyre Enhances NGS Efficiency by Eliminating Background DNA
The Next Generation Tissue Biomarkers Market is projected to grow from USD 3.02 Billion in 2024 to USD 5.98 Billion by 2030, driven by rising chronic diseases and advances in detection tech. Key highlights include the dominance of genomic biomarkers, rapid NGS growth, and increased demand for personalized medicine. The Next Generation Tissue Biomarkers Market is projected to grow from USD 3.02 Billion in 2024 to USD 5.98 Billion by 2030, driven by rising chronicBiofidelity launches Aspyre® Clinical Test for Lung, now providing next day results from tissue or blood
Simple, fast, reliable detection of non-small cell lung cancer biomarkers from tissue or blood New data to be presented at ISLB 2024 demonstrates best-in-class liquid biopsy clinical performance CAMBRIDGE, England and RESEARCH TRIANGLE PARK, N.C., Nov. 21, 2024 /PRNewswire/ --...Biofidelity launches Aspyre® Lung Reagents, now enabling integrated tissue and liquid biopsy analysis
Fast, simple, decentralized testing from tissue and blood using standard PCR instruments New data to be presented at AMP 2024 demonstrates best-in-class tissue and blood performance from both DNA and RNA CAMBRIDGE, England and RESEARCH TRIANGLE PARK, N.C., Nov. 14, 2024 /PRNewswire/ --...Biofidelity announces three senior leadership team appointments
Chief Operating Officer, Vice President of People and Chief Financial Officer will contribute to Biofidelity's growth and people priorities CAMBRIDGE, England and RESEARCH TRIANGLE PARK, N.C., Sept. 4, 2024 /PRNewswire/ -- Biofidelity, a revolutionary genomic technology company, today...
Read more news
Top Business Services Companies
Frequently Asked Questions Regarding Biofidelity
Sign Up For FreeTo access detailed company insights
Biofidelity, a private company founded in 2019 in Cambridge, UK, is revolutionizing access to best-in-class cancer diagnostics, breaking down the barriers to better screening, monitoring and treatment for all cancer patients. Its disruptive diagnostic technology platform provides oncologists with clinically actionable data based on ultra-sensitive... Read More
